Trial Profile

Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MT 0169 (Primary)
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

28 Oct 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
14 Aug 2024 According to Molecular Templates media release, trial is expected to initiate in 2H of 2024.
22 Jul 2024 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com